Pfizer (PFE)

Add to Watchlists Create an Alert
29.12 -0.18  -0.61%   NYSE May 23, 4:58PM BATS Real time Currency in USD

Pfizer R&D Expense Quarterly:

1.80B for March 31, 2013
View Full Chart

Pfizer R&D Expense Quarterly Chart

    Pfizer Historical R&D Expense Quarterly Data

    Pro Data Export
    Dates:  to
    Viewing 1 of 2   First  Previous First    Next  Last   Last

    There is no data for the selected date range.

    Data for this Date Range  
    March 31, 2013 1.80B
    Dec. 31, 2012 2.136B
    Sept. 30, 2012 1.981B
    June 30, 2012 1.699B
    March 31, 2012 2.062B
    Dec. 31, 2011 2.587B
    Sept. 30, 2011 2.176B
    June 30, 2011 2.231B
    March 31, 2011 2.091B
    Dec. 31, 2010 2.893B
    Sept. 30, 2010 2.188B
    June 30, 2010 2.181B
    March 31, 2010 2.221B
    Dec. 31, 2009 2.813B
    Sept. 30, 2009 1.632B
    June 30, 2009 1.715B
    March 31, 2009 1.705B
    Dec. 31, 2008 2.936B
    Sept. 30, 2008 1.885B
    June 30, 2008 2.122B
    March 31, 2008 Go Pro
    Dec. 31, 2007 Go Pro
    Sept. 30, 2007 Go Pro
    June 30, 2007 Go Pro
    March 31, 2007 Go Pro
       
    Dec. 31, 2006 Go Pro
    Sept. 30, 2006 Go Pro
    June 30, 2006 Go Pro
    March 31, 2006 Go Pro
    Dec. 31, 2005 Go Pro
    Sept. 30, 2005 Go Pro
    June 30, 2005 Go Pro
    March 31, 2005 Go Pro
    Dec. 31, 2004 Go Pro
    Sept. 30, 2004 Go Pro
    June 30, 2004 Go Pro
    March 31, 2004 Go Pro
    Dec. 31, 2003 Go Pro
    Sept. 30, 2003 Go Pro
    June 30, 2003 Go Pro
    March 31, 2003 Go Pro
    Dec. 31, 2002 Go Pro
    Sept. 30, 2002 Go Pro
    June 30, 2002 Go Pro
    March 31, 2002 Go Pro
    Dec. 31, 2001 Go Pro
    Sept. 30, 2001 Go Pro
    June 30, 2001 Go Pro
    March 31, 2001 Go Pro
    Dec. 31, 2000 Go Pro

    About R&D Expense

    R&D expenses are a line item from many companies' income statements.

    R&D expense (short for research and development expense) is essentially the amount of money that a company spends to develop new products and services each year. For example, if a pharmaceutical firm hires research scientists to develop new drugs, the salaries of these researchers will generally be expensed in the R&D expense category.

    Like marketing expenses, but unlike capital expenditures, R&D expenses are subtracted from revenues every year directly. Therefore, accountants treat R&D spending as an expense rather than as an investment, though there is continuous debate over whether this is the correct classification.

    An investor looking at companies with large R&D expenditures should think hard about whether a single company's R&D spending is an expense (like buying rubber to produce tires) or whether it is an investment (like buying machinery to produce tires more efficiently). Determining the answer to that question can have a large impact on how the company is valued.
    Learn More

    Get data for

    PFE R&D Expense Quarterly Benchmarks

    Companies
    Sanofi 1.480B
    Novartis 2.297B
    Merck 1.907B

    PFE R&D Expense Quarterly Rankings

    Overall 99th percentile
    6 of 8006
    Sector 99th percentile
    3 of 686 in Healthcare
    Industry 94th percentile
    3 of 55 in Drug Manufacturers - Major

    PFE R&D Expense Quarterly Range, Past 5 Years

    Minimum 1.632B Sep 2009
    Maximum 2.936B Dec 2008
    Average 2.153B